Skip to main content
Domnica Luca AG Kato

News categories: Publication

Dysregulation of T cell homeostasis

Dysregulation of regulatory T cell homeostasis by ADAR1 deficiency and chronic MDA5 signaling

The research team of Prof. Dr. Hiroki Kato at the Institute of Cardiovascular Immunology is dedicated to understanding the intricate mechanisms of immune responses in the context of viral infections and autoimmune diseases. They are particularly interested in exploring how cytoplasmic RNA sensors, like MDA5, differentiate between viral RNAs and self-RNAs, initiating type I interferons (IFNs) as anti-viral defense. However, mutations in MDA5 can lead to autoimmune diseases. Complementary to that, Domnica Luca et al. recently published her findings in Science Advances with the title "Dysregulation of regulatory T cell homeostasis by ADAR1 deficiency and chronic MDA5 signaling."


Abstract: ADAR1 deficiency constitutively activates MDA5 and causes type I IFN-driven autoimmune diseases. We found a significant reduction in the regulatory T cell (Treg) population in patients with type I interferonopathies caused by mutations in the ADAR1 or IFIH1 gene, encoding MDA5. We analyzed the underlying mechanisms using murine models and found that Treg-specific Adar1 deletion caused peripheral Treg loss and scurfy-like lethal autoimmune disorders. Treg-specific expression of MDA5 gain-of-function mutant also reduced the peripheral Treg population via apoptosis, resulting in severe autoimmune symptoms. However, shut-down of MDA5 signaling in Adar1-deficient Tregs still induced eIF-2α-mediated protein synthesis shut-off, leading to Treg loss and lethality. Altogether, our results highlight the dysregulation of Treg homeostasis in Adar1 deficiency as a key determinant for type I interferonopathies.

Publication:

Luca, D., et al. (2024)

Dysregulation of regulatory T cell homeostasis by ADAR1 deficiency and chronic MDA5 signaling

Science Advances

DOI: 10.1126/sciadv.adk0820

Related news

Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview